Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of “Hold” from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX) has received an average recommendation of “Hold” from the nine research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $27.22.

A number of equities analysts have commented on the stock. Needham & Company LLC boosted their price target on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, February 28th. HC Wainwright boosted their target price on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Barclays boosted their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th.

Institutional Investors Weigh In On Pacira BioSciences

A number of institutional investors and hedge funds have recently modified their holdings of PCRX. Janney Montgomery Scott LLC bought a new stake in shares of Pacira BioSciences during the third quarter worth approximately $793,000. Robeco Institutional Asset Management B.V. bought a new stake in shares of Pacira BioSciences during the third quarter worth approximately $1,053,000. Los Angeles Capital Management LLC raised its stake in shares of Pacira BioSciences by 942.7% during the third quarter. Los Angeles Capital Management LLC now owns 145,930 shares of the company’s stock worth $2,196,000 after buying an additional 131,934 shares during the last quarter. Entropy Technologies LP bought a new stake in Pacira BioSciences in the third quarter valued at approximately $207,000. Finally, Victory Capital Management Inc. increased its stake in Pacira BioSciences by 39.5% in the third quarter. Victory Capital Management Inc. now owns 122,228 shares of the company’s stock valued at $1,840,000 after purchasing an additional 34,589 shares in the last quarter. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Price Performance

NASDAQ:PCRX opened at $22.87 on Monday. The firm has a market cap of $1.06 billion, a PE ratio of -11.27 and a beta of 0.86. Pacira BioSciences has a 12 month low of $11.16 and a 12 month high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The company’s 50-day moving average price is $23.96 and its two-hundred day moving average price is $19.31.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.